NO20005833L - Humaniserte antistoffer som gjenkjenner Verotoxin II og cellelinje som produserer disse - Google Patents

Humaniserte antistoffer som gjenkjenner Verotoxin II og cellelinje som produserer disse

Info

Publication number
NO20005833L
NO20005833L NO20005833A NO20005833A NO20005833L NO 20005833 L NO20005833 L NO 20005833L NO 20005833 A NO20005833 A NO 20005833A NO 20005833 A NO20005833 A NO 20005833A NO 20005833 L NO20005833 L NO 20005833L
Authority
NO
Norway
Prior art keywords
verotoxin
humanized antibodies
recognize
produces
cell line
Prior art date
Application number
NO20005833A
Other languages
English (en)
Other versions
NO326197B1 (no
NO20005833D0 (no
Inventor
Yoh-Ichi Matsumoto
Atsuchi Imaizumi
Tsuyoshi Kimura
Tae Takedo
Man Sung Co
Maximiliano Vasques
Original Assignee
Teijin Ltd
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Ltd, Protein Design Labs Inc filed Critical Teijin Ltd
Publication of NO20005833D0 publication Critical patent/NO20005833D0/no
Publication of NO20005833L publication Critical patent/NO20005833L/no
Publication of NO326197B1 publication Critical patent/NO326197B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20005833A 1998-05-20 2000-11-17 Humaniserte antistoffer, fremgangsmate for deres fremstilling, farmasoytisk preparat, anvendelse samt cellelinje NO326197B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8657098P 1998-05-20 1998-05-20
PCT/US1999/011179 WO1999059629A1 (en) 1998-05-20 1999-05-19 Humanized antibodies that recognize verotoxin ii and cell line producing same

Publications (3)

Publication Number Publication Date
NO20005833D0 NO20005833D0 (no) 2000-11-17
NO20005833L true NO20005833L (no) 2001-01-15
NO326197B1 NO326197B1 (no) 2008-10-13

Family

ID=22199443

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005833A NO326197B1 (no) 1998-05-20 2000-11-17 Humaniserte antistoffer, fremgangsmate for deres fremstilling, farmasoytisk preparat, anvendelse samt cellelinje

Country Status (19)

Country Link
US (1) US7846435B1 (no)
EP (1) EP1079856B1 (no)
JP (1) JP4044733B2 (no)
KR (1) KR100548167B1 (no)
CN (1) CN1330375C (no)
AT (1) ATE335504T1 (no)
AU (1) AU748852B2 (no)
BR (1) BR9910589A (no)
CA (1) CA2328485C (no)
DE (1) DE69932719T2 (no)
DK (1) DK1079856T3 (no)
ES (1) ES2270598T3 (no)
IL (2) IL139571A0 (no)
NO (1) NO326197B1 (no)
NZ (1) NZ508119A (no)
PT (1) PT1079856E (no)
RU (1) RU2217166C2 (no)
WO (1) WO1999059629A1 (no)
ZA (1) ZA200006370B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910096B2 (en) 1996-11-15 2011-03-22 Trustees Of Tufts College Human neutralizing antibodies against hemolytic uremic syndrome
US8293245B2 (en) 2006-04-20 2012-10-23 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on Shiga toxin type 1 protein
WO2010085539A1 (en) 2009-01-23 2010-07-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on shiga toxin type 2 protein
WO2014191904A1 (en) * 2013-05-27 2014-12-04 Inmunova S.A. Antibodies which bind specifically the b subunit of the shiga toxin
US10167333B2 (en) * 2014-01-16 2019-01-01 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3236667B2 (ja) 1991-06-28 2001-12-10 三菱化学株式会社 ヒト型モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ並びに抗腫瘍剤
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
AU667533B2 (en) 1992-03-26 1996-03-28 Microcarb, Inc. Monospecific polyclonal antibodies to shiga-like toxins
CA2078716A1 (en) 1992-09-21 1994-03-22 Joyce De Azavedo Attaching and effacing protein of enterohemorrhagic e. coli
US5747272A (en) 1994-02-14 1998-05-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Detection of shiga-like toxins of enterohemoragic Escherichia coli
CA2116179C (en) 1994-02-22 2008-01-08 C. A. Lingwood Verotoxin pharmaceutical compositions and medical treatments therewith
CA2218601A1 (en) 1995-03-24 1996-10-03 Ophidian Pharmaceuticals, Inc. Treatment for verotoxin-producing escherichia coli
CA2163716C (en) 1995-11-24 2009-05-19 Clifford A. Lingwood Verotoxin pharmaceutical compositions and medical treatments therewith
DE19641466A1 (de) 1996-10-09 1998-04-16 Biotest Pharma Gmbh Orale Anwendung eines Immunglobulinpräparates zur Prävention des Hämolytischen Urämischen Syndroms sowie Präparat hierfür
WO1998020903A1 (en) * 1996-11-15 1998-05-22 Trustees Of Tufts College Humanized neutralizing antibodies against hemolytic uremic syndrome
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease

Also Published As

Publication number Publication date
PT1079856E (pt) 2006-12-29
JP2002515230A (ja) 2002-05-28
HK1036215A1 (en) 2001-12-28
DE69932719T2 (de) 2007-09-13
JP4044733B2 (ja) 2008-02-06
CA2328485C (en) 2011-05-03
IL139571A (en) 2009-09-22
IL139571A0 (en) 2002-02-10
NO326197B1 (no) 2008-10-13
RU2217166C2 (ru) 2003-11-27
EP1079856A1 (en) 2001-03-07
DE69932719D1 (de) 2006-09-21
AU748852B2 (en) 2002-06-13
NZ508119A (en) 2003-06-30
KR100548167B1 (ko) 2006-01-31
CN1330375C (zh) 2007-08-08
CN1301175A (zh) 2001-06-27
US7846435B1 (en) 2010-12-07
ATE335504T1 (de) 2006-09-15
NO20005833D0 (no) 2000-11-17
ZA200006370B (en) 2001-08-22
EP1079856B1 (en) 2006-08-09
KR20010052367A (ko) 2001-06-25
DK1079856T3 (da) 2006-12-04
AU4090499A (en) 1999-12-06
EP1079856A4 (en) 2002-03-13
WO1999059629A1 (en) 1999-11-25
CA2328485A1 (en) 1999-11-25
BR9910589A (pt) 2001-01-16
ES2270598T3 (es) 2007-04-01

Similar Documents

Publication Publication Date Title
MX2008007502A (es) Anticuerpos anti mn y metodos para su utilizacion.
DE69531679D1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
EP2360169A3 (en) PSMA antibodies
NO983431D0 (no) Anti-kl°emidler
NO20054351L (no) Monoklonalt antistoff og hybridom som produserer dette
BR0309254A (pt) Uso de um anticorpo anti-ctla-4
ATE370967T1 (de) Polyspezifische bindemoleküle und deren verwendung
ATE373719T1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
NZ595225A (en) Use of tnf inhibitor for treatment of erosive polyarthritis
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
ATE545657T1 (de) Tgf-beta antikörper
IL139700A (en) Immunotherapeutic composition for the treatment of prostate cancer
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
ATE509955T1 (de) Humanisierte kollagen-antikörper und damit verbundene verfahren
ATE290879T1 (de) Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
DK1479696T3 (da) Humant monoklonalt antistof, der binder til Ep-CAM, og dets anvendelse ved cancerterapi
NO20010747D0 (no) Antitrombotisk middel og humanisert anti-von Willebrand faktor monoklonalt antistoff
WO2002094853A3 (en) Antibodies specific for poly(ethylene glycol)
NO20005833L (no) Humaniserte antistoffer som gjenkjenner Verotoxin II og cellelinje som produserer disse
CY1107060T1 (el) Μονοκλωνικο αντισωμα κατευθυνομενο κατα των κυτταρων του ανθρωπινου νεφρικου καρκινωματος
WO2003072727A3 (en) EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER
DK1100829T3 (da) Anvendelse af basiliximab til behandling af rheumatoid arthritis eller hudsygdomme
PT998493E (pt) Epitopos de toxina semelhante a shigella e a sua utilizacao como vacinas e em diagnosticos

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees